Changing incidence and improved survival of gliomas
Changing incidence and improved survival of gliomas
复制标题
DOI：
10.1016/j.ejca.2014.05.019
复制
发表时间：
2014-09-01
影响因子：
8.4
通讯作者：
Visser, Otto
中科院分区：
文献类型：
--
作者：
Ho, Vincent K. Y.;Reijneveld, Jaap C.;Visser, Otto
背景：中枢神经系统（CNS）肿瘤是一种相对罕见但严重的健康负担。这项研究提供了深入了解的发病率和生存模式的胶质瘤在荷兰诊断的成年患者在1989-2010年期间，重点是胶质母细胞瘤和低级别glioma.Methods：21,085胶质瘤（不包括I级肿瘤）的数据，从荷兰癌症登记处，包括肿瘤的中枢神经系统没有病理证实。我们计算了所有胶质瘤亚型的年龄标准化发病率和估计的年百分比变化（EAPC）。粗和相对生存率估计使用从荷兰市政个人记录Database.Results的生命状态的信息：神经胶质瘤的发病率在成人中随着时间的推移而增加，从1989年的4.9每100，000到5.9在2010年（EAPC 0.7%，p < 0.001）。三分之二为星形细胞瘤，10%为少突胶质细胞瘤/少突星形细胞瘤，3%为室管膜瘤，21%未指明。在星形细胞肿瘤组中，胶质母细胞瘤的比例上升，而间变性和未特指的星形细胞瘤的比例下降。未特别指明的肿瘤也有所减少，但这只是在2005年之后才有意义。在研究期间，胶质母细胞瘤患者更经常接受化疗伴随和辅助放疗的多模式治疗。胶质母细胞瘤患者的粗两年生存率显著提高，从1989-1994年的5%提高到2006-2010年的15%，中位生存期从5.5个月提高到9个月。低级别胶质瘤的发病率并没有随着时间的推移而改变。低级别少突胶质细胞瘤和混合瘤的生存率显示出适度的improvement.Conclusions：总组的胶质瘤的发病率略有增加，减少间变性和不明肿瘤和胶质母细胞瘤的增加。在引入联合放化疗后，胶质母细胞瘤的两年生存率显著提高。除低级别星形细胞肿瘤外，低级别胶质瘤的生存率提高。(C)2014爱思唯尔有限公司版权所有。
Background: Tumours of the central nervous system (CNS) represent a relatively rare but serious health burden. This study provides insight into the incidence and survival patterns of gliomas in the Netherlands diagnosed in adult patients during the time period 1989-2010, with a focus on glioblastoma and low-grade gliomas.Methods: Data on 21,085 gliomas (excluding grade I tumours) were obtained from the Netherlands Cancer Registry, including tumours of the CNS without pathological confirmation. We calculated the age-standardised incidence rates and the estimated annual percentage change (EAPC) for all glioma subtypes. Crude and relative survival rates were estimated using information on the vital status obtained from the Dutch Municipal Personal Records Database.Results: Incidence of gliomas in adults increased over time, from 4.9 per 100,000 in 1989 to 5.9 in 2010 (EAPC 0.7%, p < 0.001). Two thirds were astrocytoma, 10% oligodendroglioma/oligoastrocytoma, 3% ependymoma and 21% were unspecified. Within the group of astrocytic tumours, the proportion of glioblastoma rose, while the proportion of anaplastic and unspecified astrocytoma decreased. Unspecified neoplasms also decreased, but this was significant only after 2005. Over the course of the study period, glioblastoma patients more often received multimodality treatment with chemotherapy concomitant and adjuvant to radiotherapy. The crude two-year survival rate of glioblastoma patients improved significantly, from 5% in the time period 1989-1994 to 15% in 2006-2010, with median survival increasing from 5.5 to 9 months. The incidence of low-grade gliomas did not change over time. Survival rates for low-grade oligodendroglial and mixed tumours show a modest improvement.Conclusions: The incidence rate for the total group of gliomas slightly increased, with a decrease of anaplastic and unspecified tumours and an increase of glioblastoma. Following the introduction of combined chemoradiation, two-year survival rates for glioblastoma significantly improved. Survival improved for low-grade gliomas except for low-grade astrocytic tumours. (C) 2014 Elsevier Ltd. All rights reserved.